PCOS is fundamentally a metabolic disorder driven by insulin resistance. Semaglutide's GLP-1 mechanism addresses this root cause — reducing insulin resistance, lowering androgens, and restoring menstrual regularity through weight loss and direct metabolic effects. Multiple studies have demonstrated meaningful improvements in PCOS-related hormonal and metabolic markers with GLP-1 agonism.
PCOS is not primarily a reproductive disorder — it is a metabolic disorder with reproductive consequences. The core pathology is insulin resistance, which drives hyperinsulinemia, which in turn stimulates ovarian androgen production. Elevated androgens disrupt follicular development, causing anovulation and the characteristic polycystic ovarian morphology. Semaglutide targets this cascade at its metabolic root through GLP-1 receptor agonism.
GLP-1 agonism improves insulin sensitivity in peripheral tissues, reducing the hyperinsulinemia that drives ovarian androgen production. This is the primary mechanism by which semaglutide benefits PCOS.
As insulin resistance improves, ovarian theca cell androgen production decreases. Studies show 20–35% reductions in free testosterone with significant weight loss on GLP-1 agonists.
Anovulation in PCOS is primarily driven by elevated androgens and insulin. As both normalize with semaglutide therapy, ovulatory cycles typically resume within 2–3 months in women who achieve ≥5% weight loss.
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
The titration schedule for PCOS follows the standard weight loss protocol — starting at 0.25 mg and escalating every 4 weeks. Most PCOS patients find the 1.0–1.7 mg range sufficient for meaningful metabolic and hormonal improvement. Escalation to 2.4 mg is appropriate when higher weight loss targets are needed.
| Phase | Weeks | Dose |
|---|---|---|
| Phase 1 | Weeks 1–4 | 0.25 mg/wk |
| Phase 2 | Weeks 5–8 | 0.5 mg/wk |
| Phase 3 | Weeks 9–12 | 1.0 mg/wk |
| Phase 4 | Weeks 13–16 | 1.7 mg/wk |
| Phase 5 | Week 17+ | 2.4 mg/wk |
Metformin remains the most widely prescribed medication for PCOS due to its long safety record and low cost. GLP-1/GIP agonists produce dramatically greater weight loss and metabolic improvement, making them increasingly preferred for PCOS patients with significant insulin resistance or obesity. Tirzepatide's dual mechanism may offer advantages over semaglutide for PCOS specifically.
| Metric | Semaglutide | Tirzepatide | Metformin |
|---|---|---|---|
| Primary mechanism | GLP-1 agonist | GIP + GLP-1 dual agonist | AMPK activation |
| Avg weight loss | ~14.9% at 68 wks | ~22.5% at 72 wks | ~2–3% (modest) |
| Insulin sensitization | Moderate-strong | Potent (dual mechanism) | Moderate (first-line) |
| Androgen reduction | Moderate (via weight loss) | Significant (via weight loss) | Moderate |
| Menstrual regularity | Moderate (with weight loss) | Strong (with weight loss) | Moderate |
| FDA approval (PCOS) | No (off-label) | No (off-label) | No (off-label, widely used) |
| Cost | High | Higher | Very low (generic) |
| Test | Timing |
|---|---|
| Fasting insulin + HOMA-IR | Baseline, then every 3 months |
| Free testosterone + SHBG | Baseline, then every 3 months |
| LH/FSH ratio | Baseline, then every 6 months |
| HbA1c + fasting glucose | Baseline, then every 3 months |
| Body weight + waist circ. | Monthly |
Semaglutide can restore ovulatory function in PCOS, which means unintended pregnancy is possible even in women who previously had irregular or absent cycles. Reliable contraception should be used unless pregnancy is actively desired.
Yes. Semaglutide addresses the core metabolic driver of PCOS — insulin resistance — by improving insulin sensitivity and reducing body weight. As insulin resistance improves, androgen production decreases, menstrual cycles regularize, and ovulatory function often restores. Multiple studies have shown meaningful improvements in PCOS-related hormonal and metabolic markers with GLP-1 agonism.
Most PCOS patients start at 0.25 mg/week and titrate to 1.0–2.4 mg/week based on tolerance and response. The 1.0–1.7 mg range produces significant insulin sensitization and weight loss for most patients. Escalation to 2.4 mg is appropriate if metabolic goals (A1c, weight, androgen levels) are not met at lower doses.
Insulin resistance improvements typically begin within 2–4 weeks at the 0.5–1 mg dose. Menstrual cycle regularization often occurs within 2–3 months as androgen levels fall with weight loss. Significant metabolic improvements (A1c, fasting insulin) are usually measurable by 12 weeks. Full hormonal normalization may take 6–12 months of consistent treatment.
Tirzepatide is likely more effective for PCOS due to its dual GIP/GLP-1 mechanism, which produces greater weight loss (~22.5% vs ~14.9%) and more potent insulin sensitization. However, semaglutide has a longer safety record and is more widely studied. Both are used off-label for PCOS; the choice depends on individual response, cost, and prescriber preference.
Yes. Semaglutide can restore menstrual regularity in PCOS by reducing insulin resistance and androgen levels. Studies show that weight loss of ≥5–10% is sufficient to restore ovulatory cycles in many women with PCOS. Menstrual regularization typically occurs within 2–3 months of achieving meaningful weight loss on semaglutide.
Yes. In PCOS, excess androgen production is driven by insulin resistance — high insulin stimulates ovarian theca cells to produce testosterone. By reducing insulin resistance, semaglutide indirectly reduces androgen production. Studies show meaningful reductions in free testosterone and DHEAS with GLP-1 agonism, typically correlating with the degree of weight loss achieved.
PCOS-related hair loss (androgenic alopecia) is driven by elevated androgens. As semaglutide reduces insulin resistance and androgen levels through weight loss, androgenic hair loss may slow or improve. However, hair regrowth is slow and results vary. GHK-Cu peptide is sometimes used adjunctively for hair follicle support.
Long-term semaglutide use in PCOS appears safe based on available data. The STEP-5 trial showed sustained efficacy and acceptable safety at 104 weeks. The main concern is that PCOS symptoms return when semaglutide is stopped, as the underlying condition is not cured. Ongoing treatment or maintenance lifestyle changes are needed to sustain benefits.
Third-party COA verified, ≥99% purity. Ships same day.
Shop Purgo LabsTirzepatide for PCOS: dual GIP/GLP-1 agonism, insulin sensitization, and comparison to semaglutide.
Retatrutide for PCOS: triple agonist mechanism, insulin sensitization, and comparison to semaglutide and tirzepatide.